OmniActive’s Lutemax 2020 showed increases in macular pigment density (MPOD)—the thickness of the macular pigment which is made up of lutein (L) and zeaxanthin isomers (Zi) which lead to significant improvements in photostress recovery and disability glare in a recent study conducted at the University of Georgia entitled LAMA II—an acronym for Lutein, Vision and Mental Acuity II. These findings of LAMA II were the subject of a paper, “Macular carotenoid supplementation improves disability glare performance and dynamics of photostress recovery,” which was published in the journal Eye and Vision, 2016 (Stringham, et al.)
Award-winning, globally-recognized Lutemax 2020 is a naturally-derived marigold extract providing all three macular carotenoids (lutein and enhanced levels of both zeaxanthin isomers—RR-and RS [meso]-zeaxanthin) at the same 5:1 ratio as found in nature. FDA-GRAS notified Lutemax 2020 is manufactured under a fully vertically integrated source.
LAMA II is the latest of multiple studies from OmniActive’s robust clinical program. The 12 month double-blind, placebo-controlled trial studying the effects of macular carotenoids supplementation on 59 young, healthy subjects who were randomly assigned to one of three groups: placebo, or 10mg L/2 Zi or 20 mg L/4 mg Zi from Lutemax 2020.
“We are delighted that long term studies like LAMA-II demonstrate the practical benefits of macular carotenoid supplementation for general healthy populations- using well-recognized methods and meaningful measures of visual performance,” said Abhijit Bhattacharya, President, OmniActive Health Technologies Ltd. “As an innovator and market leader, OmniActive is dedicated to continue our efforts in bringing relevant and exciting science to support product claims expanding the usage segments and customer categories for our industry.”
Photostress recovery is the amount of time the macula requires to return to its normal functioning level after exposure to a bright light source. Disability glare is a degradation of contrast which has been caused by a reduction in visual performance. LAMA II demonstrated that MPOD, visual performance in glare and photostress recovery significantly improved over placebo at both doses after 6 months of supplementation with additional improvements found at 12 months. The findings also suggest that lutein and zeaxanthin isomers from Lutemax 2020 is due, in part, to this unique formula that contains all three macular carotenoids—lutein, RR-zeaxanthin and RS (meso)-zeaxanthin.
The study’s finding are specifically relevant for consumers as it highlights the importance of supplementing with all three macular carotenoids to help maintain key attributes of health vision including recovery after exposure to bright lights as well as support in seeing objects against their backgrounds.
For more information on Lutemax 2020, OmniActive’s ingredients or science, please contact Lynda Doyle at email@example.com.
About OmniActive Health Technologies, Inc.
OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients, which are innovative and scientifically validated for dietary supplementation, nutritional fortification, functional food/beverage, coloring, flavor enhancement and personal care applications. The company addresses complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solutions with application support within a global regulatory framework. Whether looking for a new ingredient to add to a finished product, or an ingredient solution to enhance an existing ingredient, you will find unmatched innovation at OmniActive.
Core products include carotenoids, plant extracts and specialty functional ingredients. OmniActive leverages international R&D strengths to deploy an array of state-of-the-art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. The company’s manufacturing operations are located at multiple sites in India and are cGMP and HACCP system compliant.
About the journal Eye and Vision
Eye and Vision is an open access, peer-reviewed journal for ophthalmologists and visual science specialists. It welcomes research articles, reviews, methodologies, commentaries, case reports, perspectives and short reports encompassing all aspects of eye and vision. Topics of interest include but are not limit to: current developments of theoretical, experimental and clinical investigations in ophthalmology, optometry and vision science which focus on novel and high-impact findings on central issues pertaining to biology, pathophysiology and etiology of eye diseases as well as advances in diagnostic techniques, surgical treatment, instrument updates, the latest drug findings, results of clinical trials and research findings. It aims to provide ophthalmologists and visual science specialists with the latest developments in theoretical, experimental and clinical investigations in eye and vision.